Financials Groupe Berkem

Equities

ALKEM

FR00140069V2

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:20:05 2024-06-04 am EDT			5-day change	1st Jan Change
2.34 ^EUR	+0.43%		-4.49%	-23.53%

May. 13	Groupe Berkem Unveils BiombalanceTM and Pineol Premium, Two Active Ingredients from Its New Nutraceutical Range	CI
Apr. 30	Groupe Berkem Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025
Capitalization ¹	180.4	85.51	41.17	41.17	-
Enterprise Value (EV) ¹	184.9	101.5	54.08	68.22	67.37
P/E ratio	1,020 x	-53.7 x	153 x	23.3 x	10.6 x
Yield	0.69%	-	2.58%	1.29%	3.43%
Capitalization / Revenue	3.92 x	1.65 x	1.03 x	0.7 x	0.63 x
EV / Revenue	4.01 x	1.96 x	1.03 x	1.16 x	1.03 x
EV / EBITDA	20.1 x	12.9 x	9.09 x	7.42 x	5.5 x
EV / FCF	121 x	-20.7 x	41.1 x	-80.3 x	28.7 x
FCF Yield	0.82%	-4.83%	2.43%	-1.25%	3.49%
Price to Book	2.52 x	3.12 x	1.4 x	1.32 x	1.18 x
Nbr of stocks (in thousands)	17,685	17,685	17,595	17,595	-
Reference price ²	10.20	4.835	2.330	2.330	2.330
Announcement Date	4/19/22	5/16/23	5/7/24	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net sales ¹	40.57	46.07	51.8	52.4	58.7	65.15
EBITDA ¹	-	9.2	7.894	5.95	9.2	12.25
EBIT ¹	-	5.56	3.609	2.557	4.25	7.05
Operating Margin	-	12.07%	6.97%	4.88%	7.24%	10.82%
Earnings before Tax (EBT) ¹	-	1.497	-1.398	0.615	2	6
Net income ¹	1.441	0.534	-1.567	0.3672	1.55	3.75
Net margin	3.55%	1.16%	-3.03%	0.7%	2.64%	5.76%
EPS ²	-	0.0100	-0.0900	0.0200	0.1000	0.2200
Free Cash Flow ¹	-	1.522	-4.9	1.4	-0.85	2.35
FCF margin	-	3.3%	-9.46%	2.63%	-1.45%	3.61%
FCF Conversion (EBITDA)	-	16.54%	-	27.1%	-	19.18%
FCF Conversion (Net income)	-	285.02%	-	62.69%	-	62.67%
Dividend per Share ²	-	0.0700	-	0.0600	0.0300	0.0800
Announcement Date	11/10/21	4/19/22	5/16/23	5/7/24	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 Q4	2023 S1
Net sales ¹	12.5	-
EBITDA	-	2.794
EBIT	-	-
Operating Margin	-	-
Earnings before Tax (EBT)	-	-
Net income	-	-
Net margin	-	-
EPS	-	-
Dividend per Share	-	-
Announcement Date	5/16/23	-

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	4.46	16	16.4	27.1	26.2
Net Cash position ¹	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	0.4852 x	2.03 x	3.181 x	2.94 x	2.139 x
Free Cash Flow ¹	-	1.52	-4.9	1.4	-0.85	2.35
ROE (net income / shareholders' equity)	-	-	-5.51%	6.25%	7.4%	11.1%
ROA (Net income/ Total Assets)	-	1.51%	-2.22%	4.5%	2.2%	3.4%
Assets ¹	-	35.43	70.5	49.63	70.45	110.3
Book Value Per Share ²	-	4.050	1.550	1.670	1.760	1.970
Cash Flow per Share ²	-	-	0.0800	0.2000	-	-
Capex ¹	-	3.21	6.29	6	6.15	6.25
Capex / Sales	-	6.97%	12.15%	11.28%	10.48%	9.59%
Announcement Date	11/10/21	4/19/22	5/16/23	5/7/24	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Groupe Berkem

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.34 EUR

Average target price

4.633 EUR

Spread / Average Target

+98.01%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GROUPE BERKEM	-23.53%	44.63M
ELI LILLY AND COMPANY	+42.83%	748B
NOVO NORDISK A/S	+34.11%	598B
JOHNSON & JOHNSON	-5.70%	356B
MERCK & CO., INC.	+18.06%	325B
ABBVIE INC.	+4.63%	283B
ASTRAZENECA PLC	+17.02%	245B
NOVARTIS AG	+9.26%	211B
ROCHE HOLDING AG	-4.21%	209B
PFIZER, INC.	+2.43%	166B

Other Pharmaceuticals